CR20230577A - Composiciones de suministro de terapia y métodos para tratar perdida auditiva - Google Patents

Composiciones de suministro de terapia y métodos para tratar perdida auditiva

Info

Publication number
CR20230577A
CR20230577A CR20230577A CR20230577A CR20230577A CR 20230577 A CR20230577 A CR 20230577A CR 20230577 A CR20230577 A CR 20230577A CR 20230577 A CR20230577 A CR 20230577A CR 20230577 A CR20230577 A CR 20230577A
Authority
CR
Costa Rica
Prior art keywords
methods
hearing loss
gene therapy
therapy delivery
delivery compositions
Prior art date
Application number
CR20230577A
Other languages
English (en)
Inventor
Hao Chiang
Robert Ng
Emmanuel John Simons
Danielle R Lenz
Original Assignee
Akouos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akouos Inc filed Critical Akouos Inc
Publication of CR20230577A publication Critical patent/CR20230577A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La presente divulgación proporciona constructos que comprenden una secuencia codificante enlazada operativamente a un promotor, en donde la secuencia codificante codifica un polipéptido (por ejemplo, un polipéptido terapéutico). Constructos de ejemplo incluyen constructos de AAV. También se proporcionan métodos para usar los constructos divulgado para el tratamiento de pérdida auditiva y/o sordera.
CR20230577A 2021-05-13 2022-05-09 Composiciones de suministro de terapia y métodos para tratar perdida auditiva CR20230577A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163188450P 2021-05-13 2021-05-13
US202163251025P 2021-09-30 2021-09-30
US202163277549P 2021-11-09 2021-11-09
PCT/US2022/028396 WO2022240778A1 (en) 2021-05-13 2022-05-09 Gene therapy delivery compositions and methods for treating hearing loss

Publications (1)

Publication Number Publication Date
CR20230577A true CR20230577A (es) 2024-03-11

Family

ID=84028799

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230577A CR20230577A (es) 2021-05-13 2022-05-09 Composiciones de suministro de terapia y métodos para tratar perdida auditiva

Country Status (13)

Country Link
EP (1) EP4337226A1 (es)
JP (1) JP2024521052A (es)
KR (1) KR20240021799A (es)
AU (1) AU2022271727A1 (es)
CA (1) CA3218877A1 (es)
CO (1) CO2023017148A2 (es)
CR (1) CR20230577A (es)
DO (1) DOP2023000248A (es)
EC (1) ECSP23093588A (es)
IL (1) IL308396A (es)
MX (1) MX2023013394A (es)
PE (1) PE20240240A1 (es)
WO (1) WO2022240778A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
WO2019200016A1 (en) * 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof

Also Published As

Publication number Publication date
PE20240240A1 (es) 2024-02-16
JP2024521052A (ja) 2024-05-28
WO2022240778A1 (en) 2022-11-17
CA3218877A1 (en) 2022-11-17
ECSP23093588A (es) 2024-01-31
IL308396A (en) 2024-01-01
DOP2023000248A (es) 2024-01-31
MX2023013394A (es) 2023-12-14
EP4337226A1 (en) 2024-03-20
AU2022271727A9 (en) 2024-01-04
CO2023017148A2 (es) 2024-01-15
KR20240021799A (ko) 2024-02-19
AU2022271727A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
MX2021015753A (es) Constructo de arn.
WO2020163823A8 (en) Therapeutic agents and methods of treatment
MX2020008763A (es) Composiciones y metodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
MX2022014085A (es) Composiciones y metodos para tratar la perdida de audicion asociada a gjb2.
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
ZA202210127B (en) Codon optimized gla genes and uses thereof
MX2022004345A (es) Construcciones de igf2 variantes.
WO2022076803A8 (en) Compositions and methods for treatment of fabry disease
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
MX2020013313A (es) Terapia genica cardiaca con aav para cardiomiopatia.
WO2021087296A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
MX2023003984A (es) Metodos y composiciones para terapia genica con placofilina-2.
MX2021002041A (es) Terapia génica para el tratamiento de galactosemia.
WO2022076556A3 (en) Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MX2022014204A (es) Composiciones y metodos para tratar la perdida auditiva asociada al gen slc26a4.
CR20230577A (es) Composiciones de suministro de terapia y métodos para tratar perdida auditiva
NZ745489A (en) Gene therapy for the treatment of a retinal degeneration disease
ZA202110285B (en) Antibodies and methods of use
EP4223304A3 (en) Novel antimicrobial and anti-cancer therapy
WO2023150638A3 (en) Omicron coronavirus vaccine constructs and methods of making and using same
MX2023007800A (es) Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1.
WO2022067340A3 (en) Methods and compositions for the treatment of neurodegenerative diseases
WO2020139788A3 (en) Targeted delivery of therapeutic molecules